


Anti-Human IL-13 FITC

Catalog Number: 11-7139

Also Known As: Interleukin-13, IL13

RUO: For Research Use Only. Not for use in diagnostic procedures.



Purified human CD4⁺ cells were stimulated with immobilized Anti-Human CD3 Functional Grade Purified (cat. 16-0038), soluble Anti-Human CD28 Functional Grade Purified (cat. 16-0289), Human IL-2 (cat. 14-8029), and Human IL-4 (cat. 14-8049) for 2 days, followed by IL-2 and IL-4 for 3 days, and restimulated with PMA/Ionomycin in the presence Brefeldin A (cat. 00-4506) for 4 hours. The cells were surface stained with Anti-Human CD4 PE (cat. 12-0049) and intracellularly stained with Mouse IgG1 K Isotype Control FITC (cat. 11-4714) (left) or Anti-Human IL-13 FITC (right).

Product Information

Contents: Anti-Human IL-13 FITC


REF **Catalog Number:** 11-7139

Clone: PVM13-1

Concentration: 5 μ L (0.25 μ g)/test

Host/Isotype: Mouse IgG1

Formulation: aqueous buffer, 0.09% sodium azide, may contain carrier protein/stabilizer

 **Temperature Limitation:** Store at 2-8°C. Do not freeze. Light sensitive material.

LOT **Batch Code:** Refer to Vial

 **Use By:** Refer to Vial

 **Caution, contains Azide**

Description

The PVM13-1 antibody reacts with human interleukin-13 (IL-13). IL-13, also known as NC30, is a 12.5 kDa protein secreted by activated T helper cells, CD8⁺ T cells, and NK cells. The biological activities of IL-13 include suppression of macrophage cytotoxic activity, upregulation of IL-1RA expression and suppression of inflammatory cytokine expression.

Applications Reported

The PVM13-1 antibody has been reported for use in intracellular flow cytometric analysis.

Applications Tested

This PVM13-1 antibody has been pre-titrated and tested by intracellular flow cytometric analysis. This can be used at 5 μ L (0.25 μ g)/per test. A test is defined as the amount (μ g)/test of antibody that will stain a cell sample in a final volume of 100 μ L. Cell number should be determined empirically but can range from 10⁵ to 10⁸ cells/test.

References

Divekar AA, Khanna D, Abtin F, Maranian P, Saggar R, Saggar R, Furst DE, Singh RR. Reatment with imatinib results in reduced IL-4-producing T cells, but increased CD4(+) T cells in the broncho-alveolar lavage of patients with systemic sclerosis. *Clin Immunol.* 2011 Dec;141(3):293-303

Griffioen M, Borghi M, Schrier PI, Osanto S, Schadendorf D. Analysis of T-cell responses in metastatic melanoma patients vaccinated with dendritic cells pulsed with tumor lysates. *Cancer Immunol Immunother.* 2004 Aug;53(8):715-22.

Martin S, Wolf-Eichbaum D, Duinkerken G, Scherbaum WA, Kolb H, Noordzij JG, Roep BO. Development of type 1 diabetes despite severe hereditary B-lymphocyte deficiency. *N Engl J Med.* 2001 Oct 4;345(14):1036-40

van Halteren AG, van Etten E, de Jong EC, Bouillon R, Roep BO, Mathieu C. Redirection of human autoreactive T-cells Upon interaction with dendritic cells modulated by TX527, an analog of 1,25 dihydroxyvitamin D(3). *Diabetes.* 2002 Jul;51(7):2119-25.

Related Products

00-4506 Brefeldin A Solution (1000X)

00-8222 IC Fixation Buffer

00-8333 Permeabilization Buffer (10X)

11-4714 Mouse IgG1 K Isotype Control FITC (P3.6.2.1)

12-0049 Anti-Human CD4 PE (RPA-T4)

14-8029 Human IL-2 Recombinant Protein
14-8049 Human IL-4 Recombinant Protein
16-0038 Anti-Human CD3 Functional Grade Purified (UCHT1)
16-0289 Anti-Human CD28 Functional Grade Purified (CD28.2)

Not for further distribution without written consent.

Copyright © 2000-2010 eBioscience, Inc.

Tel: 888.999.1371 or 858.642.2058 • Fax: 858.642.2046 • www.eBioscience.com • info@eBioscience.com